Abstract
AbstractBackgroundThe efficacy and safety of tolvaptan (TLV) in patients with chronic heart failure (CHF) are unclear.AimThe aim of this study was to evaluate the efficacy and safety of tolvaptan (TLV) versus conventional therapy, primarily furosemide (FRM). In addition, the effect of the nutritional status on the efficacy of TLV was evaluated.MethodThis retrospective study included patients with CHF who were hospitalised and treated between March 2015 and February 2019, including 51 patients in the FRM group and 63 patients in the TLV group.ResultWeight loss did not differ between the FRM and TLV groups (−2.1 ± 2.1 kg vs −1.5 ± 3.5 kg, p = 0.250). After 7 days, the change in the estimated glomerular filtration rate was significantly smaller in the FRM group (56.5 ± 22.2 vs 51.9 ± 20.0 mL/min/1.73 m2, p = 0.002). There was no significant difference in serum sodium (Na) levels between days 0 and 7 in the FRM group (138.8 ± 5.2 vs 139.2 ± 3.9 mEq/L, p = 0.487). However, the serum Na level was significantly increased in the TLV group (138.4 ± 5.0 mEq/L vs 139.4 ± 4.0 mEq/L, p = 0.047). There was no significant correlation between weight loss due to diuresis and the objective prognostic nutritional index in either group.ConclusionIn hyponatremic patients with CHF, TLV may be more effective than FRM in slowing the course of renal damage and elevating serum Na levels; however, nutritional indices may not be necessary to consider while administering TLV.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call